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1 
MOTUPORAMINE MIMIC AGENTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
Certain MMA embodiments; of the subject invention such 
as, but not limited to, compounds 7 a, 7b, 12 and 14, are more 
readily synthesized via synthesis schemes of the subject 
invention, including schemes 1 and 2 shown in FIGS. 2 and 3, 
This application is related to a U.S. Provisional Applica-
tion of the same title and Applicant name filed Mar. 13, 2006, 
and assigned Ser. No. 60/781,963 to which priority is claimed 
under 35 USC §119(e). 
5 respectively. Not being held to any particular theory, it is the 
inventors belief that the large anthracene ring system can 
substitute (and behave biologically) like the 15-membered 
ring of 4a. Alternate embodiments of the subject invention 
include, but are not limited to, 14b 17, 18, 19, 20, 21, as 
BACKGROUND 
10 synthesized according to scheme 3 (FIG. 4) and compounds 
22, 23, and 24 as synthesized according to scheme 4 (FIG. 5. 
Furthermore, other embodiments of the subject invention per-
tain to the synthesis processes disclosed in FIGS. 2-5, or The nonselective delivery of drugs to both targeted tumor 
cells and healthy cells is a major shortcoming of current 
chemotherapies. Enhanced cell targeting during drug deliv- 15 
ery could diminish nonspecific toxicities by reducing uptake 
by healthy cells. Using existing cellular transporters for drug 
delivery provides opportunities for molecular recognition 
events to assist in the cell targeting process. 
portions thereof. 
Certain MMA embodiments of the subject invention, such 
as, but not limited to 7a, 7b, 12 and 14 not only are good 
anticancer agents via their cytotoxic properties, but they also 
serve as anti-metastatic agents which block the spread of 
cancer cells (a common problem encountered with cancer 
20 patients). A non-toxic anti-metastatic agent would also be of 
use to cancer patients because it could be taken as a cancer 
preventative and/or as an anti-metastatic agent along with a 
different chemotherapeutic regimen. Accordingly, cytotoxic 
agents like 7a are helpful toward halting the spread of cancer 
Ever since the published report of the discovery of motu-
poramines (see 1-3 FIG. 1), naturally occurring anti-cancer 
agents, found off the coast (Motupore Island) of new Guinea, 
the molecular structure and their bio-functions have fasci-
nated biochemists (Williams et al., J. Org Chem 1998, 
63:4838:4841; Williams et al., J. Org. Chem 2002, 67:245-
248; Roskelley et al., Cancer Res. 2001, 61:6788-6794). 
Indeed, In light of the difficulty and expense ofobtaining and 
purifying natural motuporamines, efforts have been made 
toward developing analogous compounds having similar or 
better characteristics that may be synthetically manufactured. 30 
Dihydromotuporamine C, (see 4a, FIG. 1) comprises a fif-
teen-membered ring, which is difficult to synthesize unless 
one uses expensive metal catalysts like Grubb's catalyst. 
25 as well as killing cancer cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 35 
FIG. 1 shows structures of motuporamine mimic agents. 
FIG. 2 shows a scheme for synthesizing motuporamine 
mimic agents. 
40 
FIG. 3. shows a scheme for synthesizing motuporamine 
mimic agents. 
FIG. 4 shows a scheme for synthesizing motuporamine 
mimic agents. 
In a specific embodiment, MMAs according to the subject 
invention comprise the following structure: 
Formula! 
where R is alkylaryl (wherein the aryl ring is either a benzene, 
naphthalene, anthracene or pyrene ring system and the alkyl 
chain length is either methylene, ethylene, propylene, buty-
lene, pentylene orhexylene), alkyl, cycloalkyl; 
R1 is either hydrogen or linear alkyl (methyl, ethyl, propyl, 
butyl, pentyl or hexyl) or branched alkyl (isopropyl, isobutyl, 
sec-butyl or t-butyl), or alkylaryl (wherein the aryl ring is 
either a benzene, naphthalene, anthracene or pyrene ring sys-
tem and the alkyl chain length is either methylene, ethylene, FIG. 5 shows a scheme for synthesizing motuporamine 
mimic agents. 
45 propylene, butylene, pentylene or hexylene ), 
DETAILED DESCRIPTION 
R2 is either hydrogen, alkyl, alkylaryl or aryl or equivalent 
to the -(CH2)yR3 
R3 is either hydrogen (H), or hydroxy (-OH), or alkoxy 
The invention pertains to motuporamine mimic agents 
(MMA) and synthesis thereof that are cytotoxic to cancer 
cells and optionally also inhibit their spread to other tissues 
(i.e., their metastatic behavior). The invention is based in part 
50 
(-0-alkyl) or alkylamido (-NHCOalkyl), amino (-NH2) 
or amino alkyl (-NH-alkyl), or N-alkyl, N-alkylamido, or 
Nalkylaryl,N-alkyl amino, x=l-16 and y=l-16 and pharma-
ceutically relevant inorganic salts thereof. MMA agents 
include pharmaceutically acceptable inorganic salts of the 
on the inventors' realization that less costly and easily syn-
thesized motuporamine mimic agents are needed and desired. 
According to one aspect, the subject invention pertains to 
MMAs that have similar biological potency as compound 4a 
(see FIG. 1), yet are much easier to synthesize and provide a 
cost-efficient entry into this novel drug class. It is difficult 
chemically to synthesize 4a. There are several reports (Gold- 60 
ring, W. P. D.; Weiler, L. Cytotoxic Alkaloids Motuporamines 
A-C: Synthesis and Structural Verification, Org. Letters 1999, 
1(9); 1471-1473; Furstner, A.; Rumbo, A. Ring-Closing 
Alkyne Metathesis. Stereoselective Synthesis of the Cyto-
toxic Marine Alkaloid Motuporamine C, J. Org. Chem. 2000, 65 
65(8); 2608-2611 ), which synthesize 4a through lengthy syn-
thesis steps involving expensive metal catalysts. 
55 
MMA agents (e.g., trihydrochloride salt, 3 HCl salt of skel-
eton 1 ). Other embodiments of the subject invention pertain to 
methods of synthesizing MMA agents. 
Certain preferred MMA embodiments include the follow-
ing: 
1: R=anthracen-9-ylmethyl, R1=ethyl, R2=H, R3 =NH2, 
x=3, and y=3 
2: R=anthracen-9-ylmethyl, R1=ethyl, R2=H, R3 =NH2, 
x=4, and y=4 
3: R=anthracen-9-ylmethyl, R1 =ethyl, R2=H, R3 =0H, 
x=3, and y=3 
4: R=anthracen-9-ylmethyl, R1=ethyl, 
R3=NHCOCH3, x=3, and y=3 
US 7,728,041 B2 
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5: R=anthracen-9-ylmethyl, R1=ethyl, 
R3 =0CH2CH3, x=3, and y=3 
6: R=anthracen-9-ylmethyl, R1=H, R2=H, R3=NH2, x=3, 
andy=3 
7: R=anthracen-9-ylmethyl, 
R3 =NHBOC, x=3, and y=3 
8: R=anthracen-9-ylmethyl, R1=ethyl, 
R3 =NHBOC, x=3, and y=3 
9: R=anthracen-9-ylmethyl, 
R3 =NHBOC, x=4, and y=4 
10: R=anthracen-9-ylmethyl, R1=ethyl, R2 =BOC, 
R3 =NHBOC, x=4, and y=4 
11: R=anthracen-9-ylmethyl, R1 =ethyl, R2 =H, 
R3 =NHCOR4 , where R4 is linear or branched alkyl, aryl or 
alkylaryl, x=3, and y=3 
In an alternative embodiment, MMAs according to the 
subject invention comprise the following structure: 
4 
therapeutic effect, e.g., cytotoxicity of cancer cells in a sub-
ject and/or metastatic behavior. Pharmaceutical compositions 
of the invention can comprise, for example, a Motuporamine 
Mimic Agent (MMA). The compositions can be administered 
alone or in combination with at least one other agent, such as 
stabilizing compound, which can be administered in any ster-
ile, biocompatible pharmaceutical carrier, including, but not 
limited to, saline, buffered saline, dextrose, and water. The 
compositions can be administered to a patient alone, or in 
10 combination with other agents, drugs or hormones. 
In addition to the active ingredients, these pharmaceutical 
compositions can contain suitable pharmaceutically accept-
able carriers comprising excipients and auxiliaries which 
facilitate processing of the active compounds into prepara-
15 tions which can be used pharmaceutically. Pharmaceutical 
compositions of the invention can be administered by any 
number of routes including, but not limited to, oral, intrave-
nous, intramuscular, intra-arterial, intramedullary, intrathe-
Formula II 20 
cal, intraventricular, transdermal, subcutaneous, intraperito-
neal, intranasal, parenteral, topical, sublingual, or rectal 
means. Pharmaceutical compositions for oral administration 
13: R=anthracen-9-ylmethyl, R1=ethyl, R2 =H, R3 =H, x=3 
14: R=anthracen-9-ylmethyl, R1=ethyl, R2=H, R3=BOC 
(t-butylcarbonyloxy), x=3 
15: R=anthracen-9-ylmethyl, R1=H, R2=H, R3 =H, x=3 
16: R=anthracen-9-ylmethyl, R1=H, R2=H, R3=BOC 
(t-butylcarbonyloxy), x=3 
In an alternative embodiment, MMAs according to the 
subject invention comprise the following structure: 
Formula III 
17: R=anthracen-9-ylmethyl, R1=ethyl, R2 =H, x=3 
18: R=anthracen-9-ylmethyl, R1=H, R2=H, x=3 
The following structures are those referred to in the formu-
las above: 
Formula IV 
anthracen-9-ylmethyl 
Formula V 
tert-butylcarbonyloxy (BOC group) 
Pharmaceutical Compositions 
The invention also pertains to pharmaceutical composi-
tions which can be administered to a patient to achieve a 
can be formulated using pharmaceutically acceptable carriers 
well known in the art in dosages suitable for oral administra-
tion. Such carriers enable the pharmaceutical compositions to 
25 be formulated as tablets, pills, dragees, capsules, liquids, gels, 
syrups, slurries, suspensions, and the like, for ingestion by the 
patient. 
Pharmaceutical preparations for oral use can be obtained 
through combination of active compounds with solid excipi-
30 ent, optionally grinding a resulting mixture, and processing 
the mixture of granules, after adding suitable auxiliaries, if 
desired, to obtain tablets or dragee cores. Suitable excipients 
are carbohydrate or protein fillers, such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; starch from com, 
35 wheat, rice, potato, or other plants; cellulose, such as methyl 
cellulose, hydroxypropylmethylcellulose, or sodium car-
boxymethylcellulose; gums including arabic and tragacanth; 
and proteins such as gelatin and collagen. If desired, disinte-
grating or solubilizing agents can be added, such as the cross-
40 linked polyvinyl pyrrolidone, agar, alginic acid, or a salt 
thereof, such as sodium alginate. 
Dragee cores can be used in conjunction with suitable 
coatings, such as concentrated sugar solutions, which also 
can contain gum arabic, talc, polyvinylpyrrolidone, carbopol 
45 gel, polyethylene glycol, and/or titanium dioxide, lacquer 
solutions, and suitable organic solvents or solvent mixtures. 
Dyestuffs or pigments can be added to the tablets or dragee 
coatings for product identification or to characterize the quan-
50 
tity of active compound, i.e., dosage. 
Pharmaceutical preparations which can be used orally 
include push fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a coating, such as glyc-
erol or sorbitol. Push fit capsules can contain active ingredi-
ents mixed with a filler or binders, such as lactose or starches, 
55 lubricants, such as talc or magnesium stearate, and, option-
ally, stabilizers. In soft capsules, the active compounds can be 
dissolved or suspended in suitable liquids, such as fatty oils, 
liquid, or liquid polyethylene glycol with or without stabiliz-
ers. 
60 Pharmaceutical formulations suitable for parenteral 
administration can be formulated in aqueous solutions, pref-
erably in physiologically compatible buffers such as Hanks' 
solution, Ringer's solution, or physiologically buffered 
saline. Aqueous injection suspensions can contain substances 
65 which increase the viscosity of the suspension, such as 
sodium carboxymethyl cellulose, sorbitol, or dextran. Addi-
tionally, suspensions of the active compounds can be pre-
US 7,728,041 B2 
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pared as appropriate oily injection suspensions. Suitable lipo-
philic solvents or vehicles include fatty oils such as sesame 
oil, or synthetic fatty acid esters, such as ethyl oleate or 
triglycerides, or liposomes. Non-lipid polycationic amino 
polymers also can be used for delivery. Optionally, the sus-
pension also can contain suitable stabilizers or agents which 
increase the solubility of the compounds to allow for the 
preparation of highly concentrated solutions. For topical or 
nasal administration, penetrants appropriate to the particular 
barrier to be permeated are used in the formulation. Such 10 
penetrants are generally known in the art. 
The pharmaceutical compositions of the present invention 
can be manufactured in a manner that is known in the art, e.g., 
6 
models, usually mice, rabbits, dogs, or pigs. The animal 
model also can be used to determine the appropriate concen-
tration range and route of administration. Such information 
can then be used to determine useful doses and routes for 
administration in humans. 
Therapeutic efficacy and toxicity, e.g., ED50 (the dose 
therapeutically effective in 50% of the population) and LD50 
(the dose lethal to 50% of the population), can be determined 
by standard pharmaceutical procedures in cell cultures or 
experimental animals. The dose ratio of toxic to therapeutic 
effects is the therapeutic index, and it can be expressed as the 
ratio, LD50/ED50 . 
Pharmaceutical compositions which exhibit large thera-
peutic indices are preferred. The data obtained from cell 
culture assays and animal studies is used in formulating a 
range of dosage for human use. The dosage contained in such 
compositions is preferably within a range of circulating con-
centrations that include the ED50 with little or no toxicity. The 
dosage varies within this range depending upon the dosage 
form employed, sensitivity of the patient, and the route of 
administration. 
The exact dosage will be determined by the practitioner, in 
light of factors related to the subject that requires treatment. 
by means of conventional mixing, dissolving, granulating, 
dragee making, levigating, emulsifying, encapsulating, 15 
entrapping, or lyophilizing processes. The pharmaceutical 
composition can be provided as a salt and can be formed with 
many acids, including but not limited to, hydrochloric, sulfu-
ric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be 
more soluble in aqueous or other protonic solvents than are 20 
the corresponding free base forms. In other cases, the pre-
ferred preparation can be a lyophilized powder which can 
contain any or all of the following: 150 mM histidine, 0.1 % 
2% sucrose, and 27% mannitol, at a pH range of 4.5 to 5.5, 
that is combined with buffer prior to use. 
In one embodiment, the reagent is delivered using a lipo-
some. Preferably, the liposome is stable in the animal into 
which it has been administered for at least about 30 minutes, 
more preferably for at least about 1 hour, and even more 
preferably for at least about 24 hours. A liposome comprises 30 
a lipid composition that is capable of targeting a reagent, 
particularly a polynucleotide, to a particular site in an animal, 
such as a human. Preferably, the lipid composition of the 
liposome is capable of targeting to a specific organ of an 
animal, such as the lung, liver, spleen, heart brain, lymph 35 
nodes, and skin. 
25 Dosage and administration are adjusted to provide sufficient 
levels of the active ingredient or to maintain the desired effect. 
Factors which can be taken into account include the severity 
of the disease state, general health of the subject, age, weight, 
A liposome useful in the present invention comprises a 
lipid composition that is capable of fusing with the plasma 
membrane of the targeted cell to deliver its contents to the 
cell. Preferably, the transfection efficiency of a liposome is 40 
about 0.5 µg of DNA per 16 nmole of liposome delivered to 
about 106 cells, more preferably about 1.0 µg of DNA per 16 
nmole ofliposome delivered to about 106 cells, and even more 
preferably about 2.0 µg of DNA per 16 nmol of liposome 
delivered to about 106 cells. Preferably, a liposome is between 45 
about 100 and 500 nm, more preferably between about 150 
and 450 nm, and even more preferably between about 200 and 
400 nm in diameter. 
and gender of the subject, diet, time and frequency of con-
tainer and labeled for treatment of an indicated condition. 
Such labeling would include amount, frequency, and method 
of administration. 
Normal dosage amounts can vary from 0.1 to 100,000 
micrograms, up to a total dose of about 1 g, depending upon 
the route of administration. Guidance as to particular dosages 
and methods of delivery is provided in the literature and 
generally available to practitioners in the art. Those skilled in 
the art will employ different formulations for nucleotides than 
for proteins or their inhibitors. 
In any of the embodiments described above, any of the 
pharmaceutical compositions of the invention can be admin-
istered in combination with other appropriate therapeutic 
agents. Selection of the appropriate agents for use in combi-
nation therapy can be made by one of ordinary skill in the art, 
according to conventional pharmaceutical principles. The 
combination of therapeutic agents can act synergistically to 
effect the treatment or prevention of the various disorders 
described above. Using this approach, one may be able to 
Suitable liposomes for use in the present invention include 
those liposomes standardly used in, for example, gene deliv-
ery methods known to those of skill in the art. More preferred 
liposomes include liposomes having a polycationic lipid 
composition and/or liposomes having a cholesterol backbone 
conjugated to polyethylene glycol. Optionally, a liposome 
comprises a compound capable of targeting the liposome to a 
particular cell type, such as a cell-specific ligand exposed on 
the outer surface of the liposome. 
50 
achieve therapeutic efficacy with lower dosages of each 
agent, thus reducing the potential for adverse side effects. 
Determination of a Therapeutically Effective Dose 
Any of the therapeutic methods described above can be 
applied to any subject in need of such therapy, including, for 
example, mammals such as dogs, cats, cows, horses, rabbits, 
55 monkeys, and most preferably, humans. 
EXAMPLE 1 
Synethesis ofN-(3-Amino-propyl)-N'-anthracen-9-
ylmethyl-N'-ethyl-propane-1,3-diamine, Hydrochlo-
ride salt (7a) 
The determination of a therapeutically effective dose is 60 
well within the capability of those skilled in the art. A thera-
peutically effective dose refers to that amount of active ingre-
dient which causes cytotoxicity of cancer cells in a subject 
and/or metastatic behavior which occurs in the absence of the 
therapeutically effective dose. 
Materials. Materials for Examples 1-16. Silica gel (32-63 
µm) and chemical reagents were purchased from commercial 
65 sources and used without further purification. All solvents 
were distilled prior to use. All other reactions were carried out 
under an N 2 atmosphere. 1 Hand 13C spectra were recorded at 
For any compound, the therapeutically effective dose can 
be estimated initially either in cell culture assays or in animal 
US 7,728,041 B2 
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300 or 75 MHz, respectively. TLC solvent systems are listed 
as volume percents and NH40H refers to concentrated aque-
ous NH40H. 
A solution of BOC-protected 11 (700 mg, 1.28 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 5 
10 minutes. A 4N HCl solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 7a as a yellow solid in 90% 
yield. 1H NMR (D20) o 8.23 (s, lH), 7.91 (m, 4H), 7.70 (m, 10 
2H), 7.59 (m, 2H), 4.70 (s, 2H), 3.34 (m, 2H), 3.11 (m, 4H), 
3.00 (t, 2H), 2.84 (t, 2H), 2.05 (q, 2H), 1.96 (m, 2H), 1.41 (m, 
3H); 13C NMR (D20): o 133.7, 133.1(3C),132.3 (2C), 130.7 
(2C), 128.1 (2C), 125.0 (2C), 121.1 (2C), 52.1, 51.8, 47.3, 
47.2, 39.3 (2C), 26.5, 23.5, 11.32. HRMS (FAB) calcd for 15 
C23H31Ny3HC1(M+H-3HC!t350.2591, Found 350.2588. 
EXAMPLE2 
8 
EXAMPLE4 
Synethesis of [3-(Anthracen-9-ylmethyl-ethyl-
amino )-propy l ]-(3-tert-butoxycarbony lamino-pro-
py 1)-carbamic acid tert-butyl ester (11) 
Ethylbromide (EtBr, 508 mg, 4.66 mmol) was dissolved in 
anhydrous acetonitrile and added to a stirring mixture of 
compound 10 (805 mg, 1.55 mmol) and anhydrous K2C03 
(644 mg, 4.66 mmol). The mixture was then stirred overnight 
at 7 5° C. under a N 2 atmosphere. After the confirmation of the 
disappearance of the 10 by TLC, the solution was concen-
trated under reduced pressure. The residue was dissolved in 
CH2Cl2 (20 mL) and washed three times with aqueous 
sodium carbonate. The organic layer was separated, dried 
with anhydrous Na2S04, filtered and concentrated under 
vacuum. Flash colunm chromatography of the residue gave 
11 as a light yellow oil. Yield 80%; Rf=0.35 (3% MeOH/ 
CHC13); 1 H NMR (CDC13) o 8.43 ( d, 2H), 8.25 (s, lH), 7.86 Synethesis ofN-(4-Amino-butyl)-N'-anthracen-9-
ylmethyl-N'-ethyl-butane-1,4-diamine Hydrochloride 
salt (7b) 
A solution of the respective Boe-protected precursor (simi-
lar to molecule 11 but having a 4,4-triamine sequence; 140 
mg, 0.26 mmole) was dissolved in absolute ethanol (2.28 mL) 
and stirred at 0° C. for 10 minutes. A 4N HCl solution (3.64 
mL) was added to the reaction mixture dropwise and stirred at 
20 (d, 2H), 7.43 (m, 2H), 7.37 (m, 2H), 4.34 (s, 2H), 2.78-2.92 
(m, 4H), 2.64 (m, 4H), 2.36 (m, 2H), 1.21-1.48 (m, 23H), 1.16 
(m, 2H); 13C NMR (CDCl3) o 155.7, 131.1(3C),131.0, 128.7 
(2C), 127.0 (2C), 125.2 (2C), 124.8 (2C), 124.5 (2C), 78.9, 
78.4, 53.4, 50.6, 50.0, 47.9, 45.3, 43.5, 37.1, 28.3 (6C), 26.5, 
25 11.7. HRMS (FAB) m/z calcd. for C33H47N30 4 (M+Ht 
550.3639, found 550.3619. 
0° C. for 20 minutes and then at room temperature overnight. 
The solution was co~centrated in vacuo to give 7b as a yellow 
30 
solid in 93% yield; H NMR (D20) o 8.76 (s, lH), 8.23 (m, 
4H), 7.78 (m, 2H), 7.68 (m, 2H), 5.33 (s, 2H), 3.43 (m, 2H), 
3.19 (m, 2H), 3.04 (t, 2H), 3.00 (t, 2H), 2.83 (t, 2H), 1.74 (m, 
6H), 1.47 (m, SH); 13C NMR (CD30D): 0 133.0, 132.9, 
132.6, 130.9, 129.4, 126.7, 124.3, 121.4, 53.4, 51.0, 40.1, 35 
25.8, 24.7, 24.5, 22.3, 9.7. HRMS (FAB) calcdforC25H35N3 
(M-Clt; 377.2831, Found 377.2831. 
EXAMPLE3 
EXAMPLE 5 
Synethesis ofMethanesulfonic acid 
3-(anthracen-9-ylmethyl-ethyl-amino)-propyl ester 
(17) 
To a solution of the alcohol 14b (216 mg, 0.74 mmol) and 
triethylamine (0.31mL,2.21 mmol) inCH2Cl2 (40mL) at0° 
C., methanesulfonyl chloride (253 mg, 2.21 mmol) was 
added dropwise over 30 minutes under a N 2 atmosphere. The 
reaction was stirred at 0° C. for 1 hour and slowly warmed to 
room temperature and stirred overnight under N2. The reac-
Synethesis of {3-[(Anthracen-9-ylmethyl)-amino ]-
propyl}-(3-tert-butoxycarbonylamino-propyl)-car-
bamic acid tert-butyl ester (10) 
To a stirred solution of amine 9 (1 g, 3.02 mmol) in 25% 
MeOH/CH2Cl2 (20 mL), was added a solution of 9-anthral-
dehyde 8 (0.519 g, 2.52 mmol) in 25% MeOH/CH2Cl2 (15 
mL) under N2. The mixture was stirred at room temperature 
overnight until the imine formation was complete (monitored 
40 tion was then cooled to 0° C. and a 4M NaOH solution (20 
mL) was added slowly with vigorous stirring. The organic 
phase was separated and washed with water (2x40 mL). The 
organic phase was separated and dried over anhydrous 
Na2S04, filtered and concentrated to give the product 17 as a 
45 clear oil (94%) that was used in the next step without further 
purification. 17: Rf=0.54 (1% MeOH/CH2Cl2); 1H NMR 
(CDC13) o 8.47 (d, 2H), 8.36 (s, lH), 7.98 (d, 2H), 7.52 (m, 
2H), 7.47 (m, 2H), 4.43 (s, 2H, CH2), 3.82 (t, 2H, OCH2), 3.11 
(s, 3H, CH3), 2.70 (q, 2H, NCH2), 2.51(t,2H, NCH2), 1.66 (q, by NMR). The solvent was removed in vacuo, the solid resi-
due dissolved in 50% MeOH/CH2Cl2 ( 40 mL) and the solu-
tion cooled to 0° C. NaBH4 (7 .55 mmol) was added in small 
portions to the solution and the mixture was stirred at rt 
overnight. The solvent was removed in vacuo, the solid resi-
due dissolved in CH2Cl2 (40 mL) and washed with Na2C03 
solution (10% aq. 3x30 mL). The CH2Cl2 layer was dried 55 
over anhydrous Na2S04, filtered and removed in vacuo to 
give an oily residue. The oil was purified by flash column 
chromatography (5% MeOH/CHCl3) to yield the product 10 
50 2H, CH2), 1.20 (t, 3H, CH3). 
as a pale yellow thick oil (0.38 g, 75%), Rf=0.3 (5% MeOH/ 
CHC13); 1H NMR (CDC13) o 8.39 (s, lH), 8.34 (d, 2H), 7.99 60 
(d, 2H), 7.53 (m, 2H), 7.46 (m, 2H), 4.70 (s, 2H), 3.18-3.24 
(m, 4H), 3.06 (brt, 2H), 2.85 (brt, 2H), 1.77 (brq, 2H), 1.60 
(br q, 2H), 1.44 (m, 18H); 13C NMR (CDC13) o 156.1 (2C), 
131.6, 130.3 (2C), 129.2 (2C), 127.2 (2C), 126.1(2C),125.0 
(3C), 124.2 (2C), 79.7 (2C), 53.7, 48.0, 46.0, 45.3, 44.0, 37.6, 65 
29.6, 28.7 (6C), 27.5. HRMS (FAB) m/z calcd. for 
C31H43N304 (M+Hr 522.3326, found 522.3304. 
EXAMPLE 6 
Synethesis 3-[3-(Anthracen-9-ylmethyl-ethyl-
amino )-propylamino ]-propan-1-ol (18) 
The mesylate 17 (384 mg, 1.04 mmol) and 3-amino-pro-
panol (392 mg, 5.25 mmol) were dissolved in acetonitrile (20 
mL). The mixture was then stirred at 75° C. under a N2 
atmosphere overnight. After the confirmation of the disap-
pearance of the mesylate by TLC, the solution was concen-
trated under reduced pressure. The residue was dissolved in 
CH2Cl2 (20 mL) and washed three times with aqueous 
sodium carbonate. The organic layer was separated, dried 
with anhydrous Na2S04, filtered and concentrated under 
vacuum. Flash colunm chromatography of the residue gave 
18 as a light yellow oil.Yield 65%; Rf=0.35 (1:6:83 NH40H: 
US 7,728,041 B2 
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MeOH:CH2 Cl2 ); 1H NMR (CDCl3) o 8.32 (d, 2H), 8.23 (s, 
lH), 7.83 (d, 2H), 7.37 (m, 2H), 7.30 (m, 2H), 4.28 (s, 2H), 
3.48 (t, 2H), 2.S6 (q, 2H), 2.30 (t, 2H), 2.12 (t, 2H), 2.06 (t, 
2H), 1.36 (q, 2H), 1.21 (q, 2H), 1.09 (t, 3H); 13C NMR 
(CDCl3) o 131.3, 131.2, 130.S, 129.3, 129.0, 127.3, l2S.S, 5 
12S.3, 124.8, 124.8, 63.8, S0.8, SO.S, 49.S, 48.3, 47.7, 30.S, 
26.6, 11.7. HRMS (FAB) m/z calcd. forC23H30N20 (M+Ht 
3Sl.2431; found 3Sl.2430. 
EXAMPLE6 10 
10 
3.lS (t, 2H), 2.84 (t, 2H), 2.73 (t, 2H), 1.79 (m, 4H), 1.47 (t, 
3H), l.lS (t, 3H); 13C NMR (D20): o 133.9, 133.S, 132.S, 
130.9, 128.4, 12S.2, 122.1, 69.9, 69.3, S2.7, S2.4, S2.2, 48.1, 
47.0, 28.2, 23.S, 17.0, 11.4. HRMS (FAB) calcd for 
C25H34N2 0.2HCI (M+H-2HC!t 379.2749, Found 
379.2749. 
EXAMPLE 9 
Synthesis ofN-{3-[3-(Anthracen-9-ylmethyl-ethyl-
amino )-propy !amino ]-propy I }-acetamide (23) 
Synethesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxy-
propyl)-N-ethyl-propane-1,3-diamine (19) A saturated sodium carbonate solution (20 mL) was added 
to a vigorously stirred solution of7a (2SO mg, O.SS mmol) in 
15 CH2Cl2 (20 mL). The organic layer was separated and was 
washed twice with saturated sodium carbonate. The com-
The mesylate 17 (S84 mg, l .S7 mmol) and 3-ethoxypro-
pylamine (649 mg, 6.30 mmol) were dissolved in acetonitrile 
(30 mL). The mixture was then stirred at 7S° C. under a N2 
atmosphere overnight. After the confirmation of the disap-
pearance of the mesylate by TLC, the solution was concen-
trated under reduced pressure. The residue was dissolved in 20 
CH2 Cl2 (2S mL) and washed three times with aqueous 
sodium carbonate. The organic layer was separated, dried 
with anhydrous Na2 S04, filtered and concentrated under 
vacuum. Flash colunm chromatography of the residue gave 
bined organic layers were dried with anhydrous Na2S04, 
filtered and concentrated to give the free amine 22 as a pale 
yellow oil in 99% yield. 22: 1 H NMR (CDCl3) o 8.48 ( d, 2H), 
8.38 (s, lH), 7.97 (d, 2H), 7.47 (m, 4H), 4.47 (s, 2H), 2.70 (q, 
2H), 2.Sl (m, 4H), 2.29 (t, 2H), 2.17 (t, 2H), l.S6 (q, 2H), 1.24 
(m, SH); 13C NMR (CDCl3): 6 131.S, 131.4, 130.9, 129.1, 
127.4, 12S.6, l2S.S, l2S.2, 124.9, S0.8, S0.7, 48.3, 47.8, 40.7, 
33.7, 27.0, 12.0. 
19 as a light yellow oil. Yield 60%; Rf=0.3S (O.S:4:8S.S 25 
NH40H:MeOH:CH2 Cl2 ); 1 H NMR (CDCl3) o 8.43 ( d, 2H), 
8.29 (s, lH), 7.89 (d, 2H), 7.40 (m, 4H), 4.38 (s, 2H), 3.3S (q, 
2H), 3.2S (t, 2H), 2.62 (q, 2H), 2.44 (t, 2H), 2.27 (t, 2H), 2.23 
A mixture of compound 22 (190 mg, O.S4 mmol) and 
anhydrous K2C03 (113 mg, 0.82 mmol) in anhydrous 
CH2Cl2 was stirred at 0° C. for 10 minutes. N-Acetoxysuc-
cinimide (NHS ester, 60 mg, 0.38 mmol) was dissolved in dry 
CH2Cl2 and was added slowly to the above stirred solution at 
0° C. under N2 atmosphere. The mixture was then stirred for 
30 minutes at 0° C. and then slowly allowed to come at room 
(t, 2H), l.S4 (q, 2H), 1.41(q,2H), 1.14 (m, 6H); 13C NMR 
(CDCl3) o 131.3, 131.2, 130.6, 128.9, 127.2, 12S.4, l2S.O, 30 
124.7, 69.1, 66.0, S0.7, S0.6, 48.2, 47.S, 47.2, 30.1, 27.1, lS.4, 
11.9. temperature and stirred for 8 hrs. After the confirmation of the 
disappearance of the ester by TLC in CH2Clihexane (7:3), 
the solution was filtered and concentrated under reduced EXAMPLE 7 
Synethesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxy-
propyl)-N-ethyl-propane-1,3-diamine, Hydrochlo-
ride salt (20) 
A solution of compound 18 (200 mg, O.S7 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 
10 minutes. A 4N HCI solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 20 as a yellow solid in 9S% 
yield. 1H NMR (D20) o 8.SO (s, lH), 8.06 (m, 4H), 7.73 (m, 
2H), 7.62 (m, 2H), 4.98 (s, 2H), 3.64 (t, 2H), 3.39 (q, 2H), 3.13 
35 pressure. The residue was dissolved in CH2Cl2 (20 mL) and 
washed three times with aqueous sodium carbonate. The 
organic layer was separated, dried with anhydrous Na2S04, 
filtered and concentrated under vacuum. Flash column chro-
matography of the residue gave 23 as a light yellow oil. Yield 
40 67%; Rf=0.30 (7% MeOH: 1% NH40H: 82% CH2 Cl2 ); 1H 
NMR (CDCl3) o 8.43 (d, 2H), 8.3S (s, lH), 7.9S (d, 2H), 7.23 
(m, 4H), 6.84 (br t, lH), 4.43 (s, 2H), 3.0S (q, 2H), 2.71 (q, 
2H), 2.43 (t, 2H), 2.20 (t, 2H), 2.09 (t, 2H), 2.78 (s, 3H), 2.48 
(q, 2H), 1.21 (m, SH); 13C NMR (CDCl3) 0 170.0, 131.4, 
45 131.3, 130.6, 129.1, 127.S, 12S.7, 124.9, 124.9, S0.6, 48.1, 
48.0, 48.0, 39.0, 28.2, 26.6, 23.4, 11.8. HRMS (FAB) m/z 
calcd. for C25H33N30 (M+Ht 392.2701, found 392.2709. 
(t, 2H), 2.90 (t, 2H), 2.76 (t, 2H), 1.79 (q, 2H), 1.44 (m, SH); 
13C NMR (D20): o 133.8, 133.4, 132.4, 130.8, 128.3, 12S.1, 
121.8, 61.4, S2.4, S2.l, S2.0, 48.0, 47.0, 30.S, 23.4, 11.3. 50 
HRMS (FAB) calcd for C23H30N2 0.2HCI (M+H-2HCit 
3Sl.2431, Found 3Sl.2428. 
EXAMPLE 10 
Synthesis ofN-{3-[3-(Anthracen-9-ylmethyl-ethyl-
amino )-propylamino ]-propyl }-acetamide, Hydro-
chloride salt (24) 
EXAMPLES 
Synthesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxy-
propyl)-N-ethyl-propane-1,3-diamine, Hydrochlo-
ride salt (21) 
A solution of compound 19 (169 mg, OAS mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 
10 minutes. A 4N HCI solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 21 as a yellow solid in 9S% 
yield. 1HNMR(D20) o 8.SS (s, lH), 8.lO(m, 4H), 7.73 (m, 
2H), 7.62 (m, 2H), S.12 (s, 2H), 3.S2 (m, 4H), 3.43 (q, 2H), 
55 A solution of compound 23 (100 mg, 0.26 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 
10 minutes. A 4N HCI solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
60 concentrated in vacuo to give 24 as a yellow solid in 96% 
yield. 1H NMR (D20) o 8.S9 (s, lH), 8.10 (m, 4H), 7.70 (m, 
2H), 7.61 (m, 2H), S.13 (s, 2H), 3.41 (br m, 2H), 3.12 (br m, 
4H), 2.79 (brm, 4H), 1.98 (s, 3H), 1.71(q,2H), 1.43 (m, SH); 
13C NMR (D2 0): o 174.S, 131.3, 130.8, 129.8, 128.2, 12S.7, 
65 122.S, 119.1, SO.O, 49.7, 49.4, 44.9, 44.1, 36.0, 2S.S, 21.9, 
20.8, 8.7. HRMS (FAB) calcd for C25H33N30.2HCI (M+H-
2HCit 392.2701, Found 392.2702. 
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EXAMPLE 11 
Synthesis of {3-[(Anthracen-9-ylmethyl)-amino ]-
propyl}-carbamic acid tert-butyl ester (12a) 
12 
4.87 (s, 2H), 3.34 (brq, 2H), 3.14 (brt, 2H), 2.81(t,2H), 2.00 
(q, 2H), 1.40 (t, 3H); 13C NMR (D20): o 133.8, 133.3 (3C), 
132.4 (2C), 130.7 (2C), 128.2 (2C), 125.1 (2C), 121.5 (2C), 
52.0, 51.9, 39.2 (2C), 24.5, 11.3. HRMS (FAB) calcd for 
5 C20H24N2 .2HC1 (M+H-2HC!t 293.2012, Found 293.2009. 
To a stirred solution of mono-BOC protected 1,3-diamine 
15b (1 g, 5.75 mmol) in 25% MeOH/CH2 Cl2 (20 mL), was 
added a solution of 9-anthraldehyde 8 (0.99 g, 4.8 mmol) in 
25% MeOH/CH2Cl2 (15 mL) under N2 . The mixture was 
stirred at room temperature overnight until the imine forma- 10 
tion was complete (monitored by NMR). The solvent was 
removed in vacuo, the solid residue dissolved in 50% MeOH/ 
CH2 Cl2 (40 mL) and the solution cooled to 0° C. NaBH4 
(14.42 mmol) was added in small portions to the solution and 
the mixture was stirred at rt overnight. The solvent was 15 
removed in vacuo, the solid residue dissolved in CH2 Cl2 ( 40 
mL) and washed with Na2 C03 solution (10% aq. 3x30 mL). 
The CH2 Cl2 layer was dried over anhydrous Na2S04 , filtered 
and removed in vacuo to give an oily residue. The oil was 
purified by flash colunm chromatography (5% MeOH/ 20 
CHC13 ) to yield the product 12a as a pale-yellow, thick oil 
(75% ). Rf=0.3 (5% MeOH/CHC13 ); 1 H NMR (CDC13 ) o 8.20 
(m, 3H), 7.85 (d, 2H), 7.43 (m, 2H), 7.36 (m, 2H), 5.32 (t, lH), 
4.52 (s, 2H), 3.10 (q, 2H), 2.77 (t, 2H), 1.56 (q, 2H), 1.39 (s, 
9H); 13C NMR (CDC13 ) o 156.0, 131.3 (2C), 130.1 (2C), 25 
129.0 (2C), 127.0 (2C), 125.9 (2C), 124.8 (2C), 124.0 (2C), 
78.7 (2C), 48.5, 45.8, 39.4, 29.9, 28.5. HRMS (FAB) rn/z 
calcd. for C23H28N20 2 (M+Ht 365.2224; found 365.2208. 
EXAMPLE 14 
Synthesis of 
3-[ (Anthracen-9-ylmethyl)-amino ]-propan-1-ol, 14a 
To a stirred solution of3-amino -1-propanol, 15a (0.87 g, 
11.65 mmol) in 25% MeOH/CH2Cl2 (20 mL), was added a 
solution of aldehyde 8 (2.00 g, 9.7 mmol) in 25% MeOH/ 
CH2Cl2 (15 mL) under N2 . The mixture was stirred at room 
temperature overnight until the imine formation was com-
plete (monitored by NMR). The solvent was removed in 
vacuo, the solid residue dissolved in 50% MeOH/CH2Cl2 ( 40 
mL) and the solution was cooled to 0° C. NaBH4 (29.1 mmol) 
was added in small portions to the solution and the mixture 
was stirred at rt overnight. The solvent was removed in vacuo, 
the solid residue dissolved in CH2Cl2 (40 mL) and washed 
with 10% aq. Na2C03 solution (3x30 mL). The CH2 Cl2 layer 
was separated, dried over anhydrous Na2S04 , filtered and 
removed in vacuo to give an oily residue. The oil was purified 
by flash colunm chromatography (6% MeOH/CHCl3 ) to 
yield the product 14a as a pale yellow thick oil (78%), Rf=0.3 
(6% MeOH/CHCl3 ); 1H NMR (CDC13 ) o 8.39 (s, lH), 8.27 
(d, 2H), 7.99 (d, 2H), 7.52 (m, 2H), 7.45 (m, 2H), 4.71(s,2H), 
EXAMPLE 12 30 3.79 (t, 2H), 3.09 (t, 2H), 1.74 (q, 2H). 
Synthesis of [3-(Anthracen-9-ylmethyl-ethyl-
amino )-propyl]-carbamic acid tert-butyl ester (12b) 
Bromoethane ( 489 mg, 4.48 mmol) was dissolved in anhy- 35 
drous acetonitrile and was added to the stirring mixture of 
compound 12a (545 mg, 1.5 mmol) and anhydrous K2 C03 
(620 mg, 4.48 mmol). The mixture was then stirred at 75° C. 
under a N2 atmosphere overnight. After the confirmation of 
the disappearance of the 12a by TLC, the solution was con- 40 
centrated under reduced pressure. The residue was dissolved 
in CH2 Cl2 (20 mL) and washed three times with aqueous 
sodium carbonate. The organic layer was separated, dried 
with anhydrous Na2 S04 , filtered and concentrated under 
vacuum. Flash colunm chromatography of the residue gave 45 
12b as a light yellow oil. Yield 80%; Rf=0.35 (3% MeOH/ 
CHC13 ); 1 H NMR (CDC13 ) o 8.39 ( d, 2H), 8.30 (s, lH), 7.90 
(d, 2H), 7.40 (m, 4H), 4.54 (br t, lH), 4.37 (s, 2H), 2.74 (q, 
2H), 2.60 (q, 2H), 2.39 (t, 2H), 1.44 (q, 2H), 1.31 (m, 9H), 
1.12 (t, 3H); 13C NMR (CDC13 ) o 155.7, 131.3 (2C), 131.2 50 
(2C), 130.4 (2C), 129.0 (2C), 127.5 (2C), 125.7 (2C), 124.8 
(2C), 78.3, 50.6, 50.5, 47.7, 39.1, 28.6 (3C), 26.6, 11.8. 
HRMS (FAB)m/zcalcd. forC25H32N2 0 2 (M+Ht 393.2537; 
found 393.2523. 
EXAMPLE 15 
Synthesis of 
3-(Anthracen-9-ylmethyl-ethyl-amino )-propan-1-ol, 
14b 
Bromoethane ( 616 mg, 5 .65 mmol) was dissolved in anhy-
drous acetonitrile and was added to the stirring mixture of 
compound 14a (500 mg, 1.9 mmol) and anhydrous K2C03 
(781 mg, 5.7 mmol). The mixture was then stirred overnight 
at 75° C. under a N2 atmosphere. After confirmation of the 
disappearance of 14a by TLC, the solution was concentrated 
under reduced pressure. The residue was dissolved in CH2Cl2 
(20 mL) and washed three times with aqueous sodium car-
bonate. The organic layer was separated, dried with anhy-
drous N a2 SO 4 , filtered and concentrated under vacuum. Flash 
colunm chromatography of the residue gave 14b as a light 
yellow oil. Yield 82%; Rf=0.35 (3% MeOH/CHCl3 ); 1H 
NMR (CDC13 ) o 8.28 (m, 3H), 7.86 (d, 2H), 7.44 (m, 2H), 
7.36 (m, 2H), 4.29 (s, 2H), 3.15 (t, 2H), 2.65 (q, 2H), 2.52 (t, 
2H), 1.43 (q, 2H), 1.16 (t, 3H); 13C NMR (CDC13 ) o 131.2, 
131.1, 129.3, 129.0, 127.6, 125.8, 124.8, 124.4, 63.4, 52.6, 
50.5, 47.7, 28.1, 11.6. HRMS (FAB) rn/z calcd. for 
55 C20H23NO (M+Hr 294.1852; found294.1859. 
EXAMPLE 13 
Synthesis ofN1-Anthracen-9-ylmethyl-N1-ethyl-
propane-l,3-diamine, Hydrochloride salt (12c) 
A solution of 12b (400 mg, 1.02 mmole) was dissolved in 
absolute ethanol (13 mL) and stirred at 0° C. for 10 minutes. 
60 
A 4N HCl solution (22 mL) was added to the reaction mixture 
dropwise and stirred at 0° C. for 20 minutes and then at room 
temperature overnight. The solution was concentrated in 65 
vacuo to give 12c as a yellow solid in 90% yield. 1H NMR 
(D20) o 8.42 (s, lH), 8.0 (m, 4H), 7.71(m,2H), 7.61(m,2H), 
EXAMPLE 16 
Synthesis of 
Nl-Anthracen-9-ylmethyl-propane-1,3-diamine, 
Hydrochloride salt (16) 
A solution of 12a (200 mg, 0.51 mmole) was dissolved in 
absolute ethanol ( 6 mL) and stirred at 0° C. for 10 minutes. A 
4N HCl solution (10 mL) was added to the reaction mixture 
dropwise and stirred at 0° C. for 20 minutes and then at room 
temperature overnight. The solution was concentrated in 
US 7,728,041 B2 
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vacuo to give 16 as a yellow solid in 90% yield. 1 H NMR 
(CD30D) o 8.69 (s, lH), 8.39 (d, 2H), 8.15 (d, 2H), 7.74 (m, 
2H), 7.60 (m, 2H), 5.33 (s, 2H), 3.45 (t, 2H), 3.12 (t, 2H), 2.23 
(q, 4H); 13C NMR (CD30D): o 6 132.6, 132.0, 131.6, 130.6, 
129.0, 126.7, 124.0, 122.5, 46.6, 44.6, 38.1, 25.4. HRMS 5 
(FAB) calcd for C18H20N2 .2HCI (M+H-2HCit 265.1699, 
Found 265.1704. 
EXAMPLE 17 
14 
shown in Table 2, all of the derivatives gave medium to high 
levels of inhibition in the assay, except 4b and 7b. In this 
regard, most of the new materials provided similar inhibition 
as 4a. 
Note: the disc assay itselfis binary. The tested compound is 
either as good as or worse than 4a. Compounds that are better 
than 4a will only give the same maximal response (90-100% 
inhibition). Future work will be necessary to see which of the 
most active compounds (6a, 6b, 7a, 12c, 13b, 16, 20, 21, and 
Biological evaluation of polyamine derivatives 
10 24) are best in vivo in terms of slowing the spread of cancers 
(anti-metastatic activity). 
Fly Stocks: 20 female and 5 male wild type Oregon variant 
of Drosophila melanogaster interbred in blue food medium 
for 24 hours then flies are removed. Third instar wall-crawl-
15 ing larvae collected then dissected on the sixth day. Flies kept 
in 25° C. incubation chamber. 
In terms of Table 1, L1210 cells are mouse leukemia cells 
and are the gold standard in terms of evaluating polyamine 
cytotoxicity data due to a plethora of prior data in this cell line 
for other polyamine structures. Clearly 7a was similar in all 
respects to 4a (Table 1 ). The fact that similar alterations in the 
structure of 7a and 4a gave the same biological response 
suggests that they are hitting the same biological target. Low 
IC50 values in Table 1 suggest greater cytotoxicity of the drug. 20 
The lower the K, value, the higher the affinity of the drug for 
the polyamine transporter (PAT) on the cell surface. Chinese 
hamster ovary (CHO) cells and a mutant line without an 
active PAT (CHO-MG) also evaluated the PAT selectivity of 
these drugs. High (CHO-MG/CHO) IC50 ratios suggest a 25 
highly selective PAT substrate. Inspection ofTable 1 suggests 
that 7 a is an effective mimic of 4a (both have low IC50 values), 
but does not use the PAT for cellular entry (both have low 
CHO-MG/CHO IC50 ratio). 
TABLE 1 
Blue Food Preparation: Standard corn meal medium 
heated then mixed completely with aqueous 1 % Bromophe-
nol Blue. The food medium is cooled for one day or more 
before use. 
Dissection Medium: Ringer's Buffer with 10 uL 0.1% 
BSA. Ringer's Medium consists of 130 mM NaCl, 5 mM 
KC!, 1.5 mM CaCl2 -2H20. Stored at room temperature (23° 
C.), BSA added before dissection. 
Cultivation Medium: Minimal Robb's Medium with 10 uL 
0.1 % BSA. Minimal Robb's Medium consists of 40 mMKCI, 
0.4 mM KH2P04 , 40 mM NaCl, 0.4 mM NaH2 P04 -7H2 0, 
1.2 mM MgS04 - 7H20, 1.2 mM MgCl2 -6 H20, 1 mM 
Biological evaluation ofpolyamine derivatives in L1210. CHO and CHO-MG cells.a 
L1210 L1210 CHO-MG CHO 
Compd (tether) IC50 inµM K, value (µM) Ref IC50 inµM IC50 inµM 
4a: dihydroMotu (3 ,3) 3.0 (±0.5) 9.9 (±0.5) 10.0 (±2.6) 10.5 (±1.6) 
4b: dihydroMotu (4,4) 18.5 (±2.9) 6.2 (±0.5) 28.2 (±5.6) 30.0 (±4.1) 
6a: Ant-methyl (3,3) 1.8 (±0.4) 33.4 (±2.6) 3.4 (±0.5) 1.9 (±0.4) 1.8 
6b: Ant-methyl (4,4) 0.30 (±0.04) 1.8 (±0.1) 66.7 (±4.1) 0.45 (±0.10) 148 
6c: Ant-ethyl (4,4) 3.5 (±0.7) 1.6 (±0.1) 33.5 (±7.1) 9.8 (±1.1) 3.4 
6d: Ant-propyl (4,4) 76.3 (±4.8) 1.1 (±0.1) 130.8 (±5.5) 130.1 (±7.1) 
7a: N 1-ethyl-N1-Ant- 2.2 (±0.1) 23.5 (±0.9) 4.0 (±0.3) 5.3 (±0.4) 0.8 
methyl (3,3) 
7b: N 1-ethyl-N1-Ant- 22.2 (±1.2) 24.4 (±1.5) 21.9 (±0.9) 22.2 (±0.7) 
methyl (4,4) 
aDefinitions used in Table 1, colunm 1: Ant~ anthracen-9-yl, dihydroMotu ~ dihydromotuporamine; column 4: 
Ref denotes the reference number in which the data was originally reported. A blank in the Ref column denotes 
new data. Cells were incubated for 48 h with the respective conjugate. 
bThe IC50 ratio denotes the (CHO-MG/CHO) IC50 ratio, a measure of PAT selectivity. 
EXAMPLE 18 50 
Inhibition ofMotuporamine Mimic Agents 
CaCl2 -2 H20, 10 mM Glucose, 0.2 mM L-asparagine, 4.0 
mM L-glutamine, 0.16 mM Glycine, 0.64 mM L-leucine, 
0.32 mM L-proline, 0.16 mM R-Serine, 0.64 mM L-valine. 
Storedat-25° C. One day before dissection, aliquot defrosted 
55 in 4 ° C. Add BSA then warmed to room temperature (23 ° C.) before dissection. 
DihydroMotuporamine C, 4a, was used to develop an 
imaginal disc assay in Drosophila flies. The imaginal leg 
discs were collected by microscopic dissection from mag-
gots. The assay reproducibly showed that (at 18 µM) 4a gave 
very high inhibition (~87%) of development of the imaginal 
disc (Table 2). Inhibition was measured as failure of the disc 60 
to fully develop into a fly leg after 15 hr of incubation in 
Robb's growth medium. This presumably occurs by overac-
tivation of Rho, an important signaling pathway in develop-
ment. Hyper-stimulation ofthis pathway is sufficient to block 
development of the fly leg. 
Using this concentration (18 µM) the panel of mimics were 
assayed (4, 6a, 6b, 7a, 7b, 12c, 13b, 16, 20, 21, and 24). As 
0.1% BSA: 0.1 g BSA fraction V (Sigma#A-9647) in 10 
mL distilled H20. Stored at 4° C. 
Developmental Hormone: 1 mg 20-hydroxyecdysone 
(Sigma #H-5142) in 1mL100% Ethanol. Stored at -25° C. 
Before use, stock is diluted 1 Ox (1 mL added to 9 mL of 100% 
Ethanol). 10 µL of diluted 20-hydroxyecdysone is added to 
culture. 
Dissection Procedures: Third instar larvae are removed 
65 from cultivation bottle with a wetted brush and washed in 
dH20 to remove food medium clinging to larvae. The cleaned 
larvae are dissected in Ringer's Medium using forceps. The 
US 7,728,041 B2 
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imaginal discs are washed in fresh Ringer's Medium, and 
then cultivated with 1 mL of Robb's Medium in 12-well 
culture plate. Each culture well should have 30-40 imaginal 
discs. 
Culturing Procedures: In a larger container, place the 
12-well culture plate on a moist towel, then seal the large 
container. Cultivate at 25° C. for 15 hours. Evaluation: Three 
categories will be used to grade the eversion of each imaginal 
disc. Full Eversion-the leg is fully extended from the disc. 
Partial Eversion-the leg is protruding from the epithelial. 10 
No Eversion-no sign of any protrusion. 
TABLE2 
Eversion Inhibition by new compounds at 
18 µM in an Imaginal Disc Assay" 
Compound % Inhibition 
4a (Motu 3,3) 87 
4b (Motu 4,4) 0 
6a (Ant 3,3) 60 
6b (Ant4,4) 97 
7a (AntNEt 3,3) 95 
7b (AntNEt4,4) 
12c (AntNEtDiamine 3) 79 
13b (Ant Diamine 4) 91 
16 (Ant Diamine 3) 92 
38 
15 
20 
25 
16 
of Formula I, or a pharmaceutically acceptable salt thereof, 
and a pharmaceutically acceptable carrier, wherein Formula I 
JS: 
wherein R is anthracen-9-ylmethyl; 
R1 is ethyl; 
R2 is hydrogen, or BOC; 
R3 is NH2 or NHBOC; and 
x=l-16 and y=l-16. 
Formula! 
2. The composition of claim 1, wherein said composition 
comprises one or more compounds of Formula I wherein: 
R=anthracen-9-ylmethyl, R1 =ethyl, R2=H, R3=NH2, x=3, 
andy=3; 
R=anthracen-9-ylmethyl, R1 =ethyl, R2=H, R3=NH2, x=4, 
andy=4; 
R=anthracen-9-ylmethyl, R1=ethyl, 
R3=NHBOC, x=3, and y=3; or 
R=anthracen-9-ylmethyl, R1=ethyl, 
R3=NHBOC, x=4, and y=4. 20 (Ant NEt aminoalcohol 3,3) 
21 (AntNEt amino ether 3 ,3) 36 
24 (AntNEt acetamide 3,3) 58 
aThe error is typically near 10-15% for this type of developmental measure-
ment. 
3. A method of killing cancer cells in a patient in need 
thereof comprising administering one or more compounds 
according to Formula I or II, or a pharmaceutically acceptable 
30 salt thereof, effective to kill cancer cells in said patient, 
wherein Formula I is: 
While various embodiments of the present invention have 
been shown and described herein, it will be obvious that such 
embodiments are provided by way of example only. Numer-
ous variations, changes and substitutions may be made with- 35 
out departing from the invention herein. Accordingly, it is 
intended that the invention be limited only by the spirit and 
scope of the appended claims. The teachings of all references 
cited herein are incorporated in their entirety to the extent not 
inconsistent with the teachings herein. 
What is claimed is: 
1. A pharmaceutical composition cytotoxic to cancer cells 
wherein said composition comprises one or more compounds 
40 
wherein R is anthracen-9-ylmethyl; 
R1 is ethyl; 
R2 is hydrogen or BOC; 
R3 is NH2 or NHBOC; and 
x=l-16 and y=l-16. 
* * * * * 
Formula! 
